17723results about How to "Reduce adverse effects" patented technology

Medical devices, and in particular implantable medical devices, may be coated to minimize or substantially eliminate a biological organism's reaction to the introduction of the medical device to the organism. The medical devices may be coated with any number of biocompatible materials. Therapeutic drugs, agents or compounds may be mixed with the biocompatible materials and affixed to at least a portion of the medical device. These therapeutic drugs, agents or compounds may also further reduce a biological organism's reaction to the introduction of the medical device to the organism. In addition, these therapeutic drugs, agents and/or compounds may be utilized to promote healing, including the formation of blood clots. Various materials and coating methodologies may be utilized to maintain the drugs, agents or compounds on the medical device until delivered and positioned.

An assembly to be detachably mounted on a body fluid monitoring system is provided. The assembly has a lancet and a device for collecting and detecting a body fluid. The lancet has a puncture needle. In this assembly, the puncture needle is maintained in sterilized conditions until its use, and the sterilization can be conducted with no adverse effects on the detection device. A readily sterilizable lancet unit and a body fluid-collecting and detecting unit adapted for use in such an assembly as well as a body fluid-monitoring system including such an assembly are also provided. The assembly comprises a first housing having a sleeve which movably accommodates the lancet in its interior, and a second housing having the body fluid detection device. The first housing and the second housing share an opening. The lancet is sterilized before the assembly. The body fluid-collecting and detecting section has a body fluid guide on the periphery of the inlet.

Methods of treating, preventing and/or managing a myeloproliferative disease are disclosed. Specific methods encompass the administration of an immunomodulatory compound, or a pharmaceutically acceptable salt, solvate, hydrate, stereoisomer, clathrate, or prodrug thereof, alone or in combination with a second active agent, and/or the transplantation of blood or cells. Particular second active agents are capable of suppressing the overproduction of hematopoietic stem cells or ameliorating one or more of the symptoms of a myeloproliferative disease. Pharmaceutical compositions, single unit dosage forms, and kits suitable for use in methods of the invention are also disclosed.

A neutral particle beam processing apparatus comprises a workpiece holder (20) for holding a workpiece (X), a plasma generator for generating a plasma in a vacuum chamber (3), an orifice electrode (5) disposed between the workpiece holder (20) and the plasma generator, and a grid electrode (4) disposed upstream of the orifice electrode (5) in the vacuum chamber (3). The orifice electrode (5) has orifices (5a) defined therein. The neutral particle beam processing apparatus further comprises a voltage applying unit for applying a voltage between the orifice electrode (5) and the grid electrode (4) via a dielectric (5b) to extract positive ions from the plasma generated by the plasma generator and pass the extracted positive ions through the orifices (5a) in the orifice electrode (5).

The present invention provides an improved antenna system that, in one embodiment, includes an antenna array comprised of a plurality of elements, each of which is capable of providing a signal. Also included in the improved antenna system is a multi-beam beamformer for producing two spatially independent overlapping beams from the signals provided by two different subsets of the antenna array. The phase of the two beams is compared to realize an interferometer that can provide high or fine resolution data on the position of an object relative to the antenna system. The amplitude of the two beams can also be compared to obtain coarse data on the position of the object. The beamformer includes a switching network for selecting which elements of the antenna array form the two subsets. This permits, for example, the position of the beams to moved, the baseline of the two beams to be varied, and/or the beam width of the beams to be altered. To reduce adverse aerodynamic effects in certain applications, the antenna array is located conformal to the exterior surface of the body on which the array is mounted. Further, to reduce temperature related problems associated with high speed movement of the body on which the array is located, the array is located on the side of the body, as opposed to the front of the body. The side location also provides space for other types of sensors that are preferably located adjacent to the front surface of the body.

An electro-optic display comprises first and second substrates and a lamination adhesive layer and a layer of a solid electro-optic material disposed between the first and second substrates, the lamination adhesive layer having a volume resistivity, measured at 10° C., which does not change by a factor of more than about 3 after being held at 25° C. and 45 percent relative humidity for 1000 hours. The electro-optic material is preferably an encapsulated electrophoretic material. Other desirable characteristics of lamination adhesives for use in electro-optic displays are also described.

This invention relates to methods for treating or preventing hepatitis C virus infections in mammals using Toll-Like Receptor (TLR)7 ligands and prodrugs thereof. More particularly, this invention relates to methods of orally administering a therapeutically effective amount of one or more prodrugs of TLR7 ligands for the treatment or prevention of hepatitis C viral infection. Oral administration of these TLR7 immunomodulating ligands and prodrugs thereof to a mammal provides therapeutically effective amounts and reduced undesirable side effects.

A method and device which dynamically detects, tracks and filters interfering signals with sufficient speed (i.e. within one IS-95 CDMA data frame period, or 20ms and fidelity to eliminate or greatly reduce the deleterious effects of narrow band interferor signals on a CDMA link. When inserted in an RF signal path an Adaptive Notch Filter (ANF) detects narrow band interferors above a threshold level within the CDMA signal. Detection is accomplished by continuous scanning of a preset excision band, e.g. a specified narrow band associated with an AMPS system. Detected interferors are then automatically acquired and suppressed. This is achieved by electronically placing a rejection notch at the frequency of the interferors. Multiple notch filters may be used to simultaneously suppress multiple interferors. In the absence of interferors a bypass mode is selected allowing the RF signal to bypass the notch. Upon detection of an interferor, a switch is made to a suppression mode where the interferor is steered through a first notch section and suppressed. Alternatively, an external control line may be used to select the bypass mode so that the signal is allowed to pass the notch section, regardless of interferer content.

A masking material 13, which includes stripe-like openings 12 parallel to the [1-100] direction of a nitride semiconductor thin film, is formed on a substrate. Nitride semiconductor thin films 11 doped with Mg are grown on the openings 12 by selective-area growth. The nitride semiconductor thin films 11 are composed of a portion 14 formed as a result of the growth in the direction perpendicular to a (0001) principal plane, and a portion 15 formed as a result of the growth of {11-2x} facets (x=0, 1, 2). The Mg concentration of the portion 15 is made lower than that of the portion 14.

This invention relates to methods and compositions for treating psychiatric conditions, such as depression.

A vehicle system is disclosed that includes a vehicle lamp assembly including a plurality of LEDs that emit white light so as to function as an illuminator light. The lamp assembly also may include a plurality of LEDs that emit colored light to function as a signal light. The lamp assembly may include a camera. The lamp assembly may serve as a CHMSL or as a tail light. The system also includes a controller that rapidly pulses the LEDs at a rate that is imperceivable by the human eye. The pulsing intervals of the LEDs may be related to the readout intervals of the camera sensor array. In this manner, the LEDs may be pulsed on during camera readout to increase the illumination while the camera is capturing an image, or may be pulsed off during camera readout to prevent feedback glare from interfering with image capture by the camera.

A substrate cleaning apparatus includes a supporting unit, provided in a processing chamber having a gas exhaust port, for supporting a substrate; one or more nozzle units, each for ejecting gas clusters to a peripheral portion of the substrate supported by the supporting unit to remove unnecessary substances from the peripheral portion; and a moving mechanism for changing relative positions of the supporting unit and the nozzle unit during ejecting the gas clusters. Each nozzle unit discharges a cleaning gas having a pressure higher than that in the processing chamber so that the cleaning gas is adiabatically expanded to form aggregates of atoms and/or molecules.

An 8-oxoadenine compound useful as an immuno-modulator having specific activity against Th1/Th2, specifically a prophylactic and therapeutic agent for a topical application for allergic diseases, viral diseases and cancers, which is represented by the following formula (1):

wherein A is a group of a formula represented by the formula (2):

• • wherein R² is a substituted or unsubstituted alkyl group and so on, R³ is hydrogen atom or an alkyl group, R is a halogen atom and so on, n is 0˜2,
• X¹ is oxygen atom, Z is straight or branched chain alkylene, and R¹ is an alkyl group which is optionally substituted by hydroxy group, an alkoxy group, alkoxycarbonyl group and so on, or its pharmaceutically acceptable salt.

Embolism protection devices can be formed with a biocompatible expandable polymer that can expand upon release within a patient's vessel. Upon release, the structure can be configured to filter flow through the vessel. The material of the embolism protection devices can release one or more biologically active agents, such as a thrombolitic agent, including, for example, tPA. Alternatively or additionally, the embolism protection device can be connected to a tether that elutes one or more biologically active agents.

A method and apparatus for treating patients suffering from involuntary movement disorders (including epilepsy) by stimulating a selected cranial nerve of the patient with an electrical signal applied to induce a signal at brain by applying an electrical signal at the nerve to ameliorate the disorder and by applying a neural conduction block at the nerve selected to at least partially block nerve impulses on said nerve at a blocking site and reduce adverse effects of said signal on an organ.

A system and process for controlling the coding bit rate of streaming media data is presented where a server streams data that exhibits one of a number of coding bit rates supported by the server. Initially, the server chooses the coding bit rate. However, after this startup period, the client provides coding bit rate requests. The server transmits the streaming media data at the most appropriate supported coding bit rate closest to the rate requested. The coding bit rates requested are those estimated to provide a high quality playback of the streaming data while still keeping a decoder buffer of the client filled to a desired level. A leaky bucket model is incorporated so that the changes in buffer duration due to natural variation in the instantaneous coding bit rate are not mistaken for changes in buffer duration due to network congestion.

A method and neurostimulator for providing therapy to a patient is provided. In one technique, electrical background energy is conveyed to a first tissue region of the patient in accordance with stochastic parameter, thereby modulating the excitability of the first tissue region, and electrical stimulation energy is conveyed to the first tissue region when its excitability is modulated. In one example, the stimulation energy may be conveyed to a second tissue region of the patient, thereby therapeutically stimulating the second tissue region. In this case, the excitability of the first tissue region is decreased, thereby reducing any adverse effect that the conveyed stimulation energy has on the first tissue region. As another example, the conveyed stimulation energy stimulates the first tissue region, in which case, the excitability of the first tissue region may be increased, thereby enhancing the stimulation of the first tissue region by the conveyed stimulation energy.

A cable including circuitry for asserting information to a user or external device and a system including such a cable. The cable can include conductors, a memory storing cable data, and circuitry configured to respond to a request received on at least one of the conductors by accessing at least some of the cable data and asserting the accessed data serially to at least one of the conductors (e.g., for transmission to an external device). Other aspects of the invention are methods for accessing cable data stored in a cable and optionally using the data (e.g., to implement equalization). The cable data can be indicative of all or some of cable type, grade, speed, length, and impedance, a date code, a frequency-dependent attenuation table, far-end crosstalk and EMI-related coefficients, common mode radiation, intra pair skew, and other information. The cable can include a radiation-emitting element and circuitry for generating driving signals for causing the radiation-emitting element to produce an appropriate color, brightness, and/or blinking pattern.

The invention discloses a surgical instrument. The surgical instrument includes a handle assembly, a shaft assembly, an end effector and a nail cartridge assembly. The shaft assembly is connected to the handle assembly, the end effector is disposed at one end of the shaft assembly, and the nail cartridge assembly is mounted in the end effector. The nail cartridge assembly includes a nail cartridgebody and a nail cartridge protective cover, and the nail cartridge protective cover is detachably connected to the nail cartridge body. A barrier portion is disposed on the nail cartridge protectivecover and/or the nail cartridge body. After the nail cartridge protective cover is connected to the nail cartridge body, the barrier portion is used for forming space between the nail cartridge body and a baffle plate. According to the surgical instrument, suturing nails can be well sealed in the nail cartridge body before being fired, and the suturing nails are prevented from being separated fromthe nail cartridge body during storage and transportation due to extrusion or external force; and at the same time, the surgical instrument further solves the problem that the nail cartridge protective cover is detached from the nail cartridge assembly together with part of the suturing nails when the nail cartridge protective cover is removed.